Table 4.
Response rate, objective response rate, and disease control rate
| Response rate, n | ORR (CR + PR) | DCR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Soft tissue sarcoma subtypea | n | CR | PR | SD | SD (≥11 W) |
PD | NE | (%) | (%) |
| All | 235 | 1 | 18 | 81 | 47 | 129 | 6 | 8.1 | 42.6 |
| L-type | 135 | 1 | 7 | 60 | 37 | 64 | 3 | 5.9 | 50.4 |
| Non-L-type | 100 | 0 | 11 | 21 | 10 | 65 | 3 | 11.0 | 32.0 |
| Leiomyosarcoma | 71 | 1 | 4 | 30 | 14 | 36 | 0 | 7.0 | 49.3 |
| Liposarcoma | 64 | 0 | 3 | 30 | 23 | 28 | 3 | 4.7 | 51.6 |
| Dedifferentiated | 37 | 0 | 0 | 19 | 15 | 17 | 1 | 0.0 | 51.4 |
| Myxoid | 12 | 0 | 3 | 4 | 2 | 3 | 2 | 25.0 | 58.3 |
| Well-differentiated | 6 | 0 | 0 | 4 | 4 | 2 | 0 | 0.0 | 66.7 |
| Pleomorphic | 3 | 0 | 0 | 0 | 0 | 3 | 0 | 0.0 | 0.0 |
| Unknown | 6 | 0 | 0 | 3 | 2 | 3 | 0 | 0.0 | 50.0 |
| Undifferentiated pleomorphic sarcoma | 18 | 0 | 2 | 2 | 1 | 14 | 0 | 11.1 | 22.2 |
| Angiosarcoma | 13 | 0 | 2 | 2 | 2 | 9 | 0 | 15.4 | 30.8 |
| Synovial sarcoma | 13 | 0 | 3 | 3 | 1 | 7 | 0 | 23.1 | 46.2 |
| Rhabdomyosarcoma | 11 | 0 | 2 | 0 | 0 | 8 | 1 | 18.2 | 18.2 |
| Malignant peripheral nerve sheath tumor | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0.0 | 0.0 |
| Myxofibrosarcoma | 5 | 0 | 1 | 1 | 0 | 2 | 1 | 20.0 | 40.0 |
CR complete response rate, DCR disease control rate, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease, W weeks
aLimited to subtypes with 5 or more patients